<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009384</url>
  </required_header>
  <id_info>
    <org_study_id>BCC-MEL-11-01</org_study_id>
    <nct_id>NCT02009384</nct_id>
  </id_info>
  <brief_title>Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox</brief_title>
  <official_title>A Phase II Open-Label Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients After Regulatory T Cell Depletion With Denileukin Diftitox</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and&#xD;
      Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42&#xD;
      patients with radiographically measurable melanoma who have received at least one cycle of&#xD;
      Denileukin Diftitox will be enrolled and treated in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and&#xD;
      Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42&#xD;
      patients with radiographically measurable melanoma who have received at least one cycle of&#xD;
      Denileukin Diftitox will be enrolled and treated in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollment r/t requirement of prior treatment with denileukin diftitox&#xD;
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Using Immune-related Response Criteria (irRC)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks</time_frame>
    <description>no outcomes available, Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>administration of IV ipilimumab for up to 4 cycles</description>
    <arm_group_label>Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥18 years of age;&#xD;
&#xD;
          2. Patients with histological confirmed melanoma (Stage IIIC or Stage IV, American Joint&#xD;
             Commission on Cancer);&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2;&#xD;
&#xD;
          4. Life expectancy ≥3 months;&#xD;
&#xD;
          5. Treatment with Denileukin Diftitox within 42 days prior to first dose of Ipilimumab;&#xD;
&#xD;
          6. At least 1 site of radiographically measurable disease by immune-related response&#xD;
             criteria (irRC);&#xD;
&#xD;
          7. Adequate hematologic, renal, and liver function as defined by laboratory values&#xD;
             performed within 42 days prior to initiation of dosing:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.0 x 109/L;&#xD;
&#xD;
               -  Platelet count ≥100 x 109/L;&#xD;
&#xD;
               -  Hemoglobin ≥8 g/dL;&#xD;
&#xD;
               -  Serum creatinine ≤3 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Total serum bilirubin ≤2 x ULN;&#xD;
&#xD;
               -  Serum aspartate transaminase (AST/SGOT) or serum alanine transaminase (ALT/SGPT)&#xD;
                  ≤2x ULN, and ≤3 x ULN if liver metastases are present.&#xD;
&#xD;
          8. Fertile males should use an effective method of contraception during treatment and for&#xD;
             at least 3 months after completion of treatment, as directed by their physician;&#xD;
&#xD;
          9. Pre-menopausal females and females &lt;2 years after the onset of menopause should have a&#xD;
             negative pregnancy test at Screening. Pre-menopausal females must agree to use an&#xD;
             acceptable method of birth control from the time of the negative pregnancy test up to&#xD;
             90 days after the last dose of study drug. Females of non-childbearing potential may&#xD;
             be included if they are either surgically sterile or have been postmenopausal for ≥1&#xD;
             year;&#xD;
&#xD;
         10. Before study entry, written informed consent must be obtained from the patient prior&#xD;
             to performing any study-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with Ipilimumab;&#xD;
&#xD;
          2. Known hypersensitivity to Ipilimumab or any of its components;&#xD;
&#xD;
          3. Steroids within one week prior to initiation of Ipilimumab.&#xD;
&#xD;
          4. Pre-existing autoimmune colitis.&#xD;
&#xD;
          5. Patients with an allograft requiring immunosuppression;&#xD;
&#xD;
          6. Known positive human immunodeficiency virus (HIV)&#xD;
&#xD;
          7. Pregnant, breast-feeding, or refusing double barrier contraception, oral&#xD;
             contraceptives, or avoidance of pregnancy measures;&#xD;
&#xD;
          8. Have any other uncontrolled infection or medical condition that could interfere with&#xD;
             the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Chesney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown Cancer Center, University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <results_first_submitted>March 1, 2017</results_first_submitted>
  <results_first_submitted_qc>October 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2021</results_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Jason Chesney</investigator_full_name>
    <investigator_title>Director, James Graham Brown Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</recruitment_details>
      <pre_assignment_details>Study was Terminated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ipilimumab</title>
          <description>IV ipilimumab&#xD;
Ipilimumab: administration of IV ipilimumab for up to 4 cycles&#xD;
Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">Study was Terminated due to low subject enrollment Data was not analyzed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study was Terminated due to low subject enrollment Data was not analyzed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ipilimumab</title>
          <description>IV ipilimumab&#xD;
Ipilimumab: administration of IV ipilimumab for up to 4 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at Baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age collected by medical record</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="65" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>collected by medical record</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>based on subject address</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Using Immune-related Response Criteria (irRC)</title>
        <description>no outcomes available, Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</description>
        <time_frame>baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks</time_frame>
        <population>no outcomes available, Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>IV ipilimumab&#xD;
Ipilimumab: administration of IV ipilimumab for up to 4 cycles&#xD;
Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Using Immune-related Response Criteria (irRC)</title>
          <description>no outcomes available, Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</description>
          <population>no outcomes available, Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs During study treatment and 21 days following end of treatment will be documented and reported if applicable. Adverse events occurring between the time of signing informed consent to the date of the first dose will NOT be captured as AEs unless the AE is a direct result of a study-specific procedure or results in death from an event other than PD</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ipilimumab</title>
          <description>dosage:3 mg/kg of subject weight dosage form: Intravenous administration on Ipilimumab frequency of administration: Ipilimumab: administration of IV ipilimumab every three weeks for up to 4 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI v4.01</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade: 3 Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jason Chesney</name_or_title>
      <organization>University of Louisville</organization>
      <phone>502-562-3429</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

